A US biopharma company is seeking opportunities addressing rare and/or rare paediatric diseases through late-preclinical and clinical-stage therapeutics. The industry sponsor is a publicly-traded biopharma company based in the United States with deep experience in developing assets for rare diseases. Within its portfolio, the company currently have four late-stage programmes targeting ultra-rare paediatric diseases and rare cancers. The company also has an extensive pipeline of early/preclinical therapies in development for a variety of rare diseases.

**Approaches of Interest**

Clinical-stage or preclinical therapies targeting rare and/or rare paediatric disease that:

- Target diseases with a prevalence of at least 1 in 100,000, or addressable patient populations in the US and EU of at least 1,000 patients
- Have proof-of-concept in validated in vivo models

**Therapies of Interest**

- Novel NCEs/NMEs (New Chemical Entities / New Molecular Entities)
- Broad interest in a range of drug modalities
- Repurposed drugs with differentiated intellectual property

**Stage of Development**

- Preclinical through to phase III of clinical trials is within scope, with a preference for research in the late preclinical to clinical stage
- Opportunities with an active form of intellectual property, or a clear strategy to pursue an intellectual property is preferred

**Out of Scope**

- Therapies at the basic research stage without in vivo validation
- Approaches targeting common diseases

**Jurisdictions of Interest**

The call is open globally, with a particular interest in opportunities based in North America and Europe, and some interest in opportunities based in China, Japan, Korea, and Australia.

**Incentives for Academics**

The industry client is open to developing a range of collaborations, which they will determine on a case-by-case basis.

**Submission Information**

Submission of one page, 200-300 word briefs are encouraged. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

**Opportunities sought**

- Technologies
- Academics and expertise
- Centres of excellence
- Research projects
- Spinout companies

**Submissions**

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: 3rd August 2021 - 10:59 pm GMT

Have any questions?
Contact our team at discover@in-part.co.uk